Literature DB >> 25668122

HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs.

Sylvanne M Daniels1, Lucile Sinck, Natalie J Ward, Carlos E Melendez-Peña, Robert J Scarborough, Ibrahim Azar, Elodie Rance, Aïcha Daher, Ka-Ming Pang, John J Rossi, Anne Gatignol.   

Abstract

Several proteins and RNAs expressed by mammalian viruses have been reported to interfere with RNA interference (RNAi) activity. We investigated the ability of the HIV-1-encoded RNA elements Trans-Activation Response (TAR) and Rev-Response Element (RRE) to alter RNAi. MicroRNA let7-based assays showed that RRE is a potent suppressor of RNAi activity, while TAR displayed moderate RNAi suppression. We demonstrate that RRE binds to TAR-RNA Binding Protein (TRBP), an essential component of the RNA Induced Silencing Complex (RISC). The binding of TAR and RRE to TRBP displaces small interfering (si)RNAs from binding to TRBP. Several stem-deleted RRE mutants lost their ability to suppress RNAi activity, which correlated with a reduced ability to compete with siRNA-TRBP binding. A lentiviral vector expressing TAR and RRE restricted RNAi, but RNAi was restored when Rev or GagPol were coexpressed. Adenoviruses are restricted by RNAi and encode their own suppressors of RNAi, the Virus-Associated (VA) RNA elements. RRE enhanced the replication of wild-type and VA-deficient adenovirus. Our work describes RRE as a novel suppressor of RNAi that acts by competing with siRNAs rather than by disrupting the RISC. This function is masked in lentiviral vectors co-expressed with viral proteins and thus will not affect their use in gene therapy. The potent RNAi suppressive effects of RRE identified in this study could be used to enhance the expression of RNAi restricted viruses used in oncolysis such as adenoviruses.

Entities:  

Keywords:  Ago2, Argonaute-2; EGFP, enhanced green fluorescent protein; EMSA, electrophoresis mobility shift assay; FL, firefly luciferase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HIV, human immunodeficiency virus; HIV-1; IP, immunoprecipitation; NC, nucleocapsid; PAGE, polyacrylamide gel electrophoresis; RISC, RNA-Induced Silencing Complex; RL, Renilla luciferase; RNA interference; RNA silencing suppressor; RNAi, RNA interference; RRE, Rev Response Element; RSS, RNA silencing suppressor; RT, reverse transcription; Rev-Response Element RNA; TAR RNA Binding Protein (TRBP); TAR, trans-activation responsive element; TRBP, TAR RNA Binding Protein; Trans-Activation Response Element; UTR, untranslated region; VA, virus-associated; WT, wild-type; adenovirus; ds, double-stranded; lentiviral vectors; miRNA, micro RNA; pre-miRNA, precursor miRNA; siRNA, small interfering RNA

Mesh:

Substances:

Year:  2015        PMID: 25668122      PMCID: PMC4615856          DOI: 10.1080/15476286.2015.1014759

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  85 in total

1.  A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA.

Authors:  G Hutvágner; J McLachlan; A E Pasquinelli; E Bálint; T Tuschl; P D Zamore
Journal:  Science       Date:  2001-07-12       Impact factor: 47.728

2.  HIV-1 regulator of virion expression (Rev) protein binds to an RNA stem-loop structure located within the Rev response element region.

Authors:  S Heaphy; C Dingwall; I Ernberg; M J Gait; S M Green; J Karn; A D Lowe; M Singh; M A Skinner
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

3.  Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein.

Authors:  Hoshang J Unwalla; Hai-Tang Li; Ingrid Bahner; Ming-Jie Li; Donald Kohn; John J Rossi
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Endosomal trafficking of HIV-1 gag and genomic RNAs regulates viral egress.

Authors:  Dorothée Molle; Carolina Segura-Morales; Gregory Camus; Clarisse Berlioz-Torrent; Jorgen Kjems; Eugenia Basyuk; Edouard Bertrand
Journal:  J Biol Chem       Date:  2009-05-18       Impact factor: 5.157

Review 5.  Modulating HIV-1 RNA processing and utilization.

Authors:  Meredith McLaren; Kim Marsh; Alan Cochrane
Journal:  Front Biosci       Date:  2008-05-01

6.  The cellular TAR RNA binding protein, TRBP, promotes HIV-1 replication primarily by inhibiting the activation of double-stranded RNA-dependent kinase PKR.

Authors:  Viraj R Sanghvi; Laura F Steel
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

7.  Identification of a cis-acting element in human immunodeficiency virus type 2 (HIV-2) that is responsive to the HIV-1 rev and human T-cell leukemia virus types I and II rex proteins.

Authors:  N Lewis; J Williams; D Rekosh; M L Hammarskjöld
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

8.  Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing.

Authors:  Yamina Bennasser; Shu-Yun Le; Monsef Benkirane; Kuan-Teh Jeang
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

9.  Design of HIV vectors for efficient gene delivery into human hematopoietic cells.

Authors:  Priscilla Y Yam; Shulian Li; Jerry Wu; Jun Hu; John A Zaia; Jiing-Kuan Yee
Journal:  Mol Ther       Date:  2002-04       Impact factor: 11.454

10.  HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression.

Authors:  Zachary Klase; Rafael Winograd; Jeremiah Davis; Lawrence Carpio; Richard Hildreth; Mohammad Heydarian; Sidney Fu; Timothy McCaffrey; Eti Meiri; Mila Ayash-Rashkovsky; Shlomit Gilad; Zwi Bentwich; Fatah Kashanchi
Journal:  Retrovirology       Date:  2009-02-16       Impact factor: 4.602

View more
  9 in total

1.  Circular RNA Profiles in Viremia and ART Suppression Predict Competing circRNA-miRNA-mRNA Networks Exclusive to HIV-1 Viremic Patients.

Authors:  Dora Zucko; Abdullgadir Hayir; Kelsey Grinde; Kathleen Boris-Lawrie
Journal:  Viruses       Date:  2022-03-25       Impact factor: 5.818

2.  Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy.

Authors:  Robert J Scarborough; Kelsey L Adams; Olivier Del Corpo; Aïcha Daher; Anne Gatignol
Journal:  J Vis Exp       Date:  2016-09-05       Impact factor: 1.355

Review 3.  RNA Interference Therapies for an HIV-1 Functional Cure.

Authors:  Robert J Scarborough; Anne Gatignol
Journal:  Viruses       Date:  2017-12-27       Impact factor: 5.048

4.  ADAR1 and PACT contribute to efficient translation of transcripts containing HIV-1 trans-activating response (TAR) element.

Authors:  Evelyn Chukwurah; Indhira Handy; Rekha C Patel
Journal:  Biochem J       Date:  2017-03-23       Impact factor: 3.857

Review 5.  The Diverse Roles of microRNAs at the Host⁻Virus Interface.

Authors:  Annie Bernier; Selena M Sagan
Journal:  Viruses       Date:  2018-08-19       Impact factor: 5.048

6.  A U1i RNA that Enhances HIV-1 RNA Splicing with an Elongated Recognition Domain Is an Optimal Candidate for Combination HIV-1 Gene Therapy.

Authors:  Olivier Del Corpo; Ryan P Goguen; Camille M G Malard; Aïcha Daher; Susan Colby-Germinario; Robert J Scarborough; Anne Gatignol
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-18       Impact factor: 8.886

Review 7.  Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives.

Authors:  Roman P Labbé; Sandrine Vessillier; Qasim A Rafiq
Journal:  Viruses       Date:  2021-08-02       Impact factor: 5.048

Review 8.  Dodging the Host Interferon-Stimulated Gene Mediated Innate Immunity by HIV-1: A Brief Update on Intrinsic Mechanisms and Counter-Mechanisms.

Authors:  Kumaraswami Chintala; Krishnaveni Mohareer; Sharmistha Banerjee
Journal:  Front Immunol       Date:  2021-07-29       Impact factor: 7.561

9.  Efficient Inhibition of HIV Using CRISPR/Cas13d Nuclease System.

Authors:  Hoang Nguyen; Hannah Wilson; Sahana Jayakumar; Viraj Kulkarni; Smita Kulkarni
Journal:  Viruses       Date:  2021-09-16       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.